Emergence of Haemophilus Influenza Type A In Arctic Indigenous Populations

Thursday, 21 August 2014: 10:30 AM-12:00 PM
Tubughnenq 5 (Dena'ina Center)

The incidence of invasive infections of Haemophilus influenzae serotype b (Hib) has declined wherever protein-polysaccharide conjugate vaccines have been introduced for routine use in children. The decline of Hib disease and asymptomatic pharyngeal colonization by Hib have raised concerns about the possibility of “replacement disease” due to non-serotype-b H. influenzae filling the ecologic niche previously held by Hib. Since 2002, Hia infections have emerged among indigenous children of Alaska and Northern Canada, creating a new health disparity. The Canadian government began development of a novel Hia vaccine in 2013. In this symposium, we propose to describe what is known about the epidemiology of non-serotype b Haemophilus influenzae among indigenous North American children. We will describe plans for and progress towards a new Hia vaccine.

Thomas Hennessy, MD and Jay Butler
10:30 AM
Epidemiology of Hia in US indigenous populations
Michael G Bruce, MD, CDC Arctic Investigations Program
10:45 AM
Epidemiology in Canadian indigenous children
Raymond Tsang, PhD, Public Health Agency of Canada; Shalini Desai, MD, Public Health Agency of Canda
11:00 AM
Laboratory tests to assess Hia immunology
Marina Ulanova, PhD, Norther Ontario School of Medicine
11:15 AM
Progress toward making a Hia protein-polysaccharide conjugate
Andrew Cox, PhD, National Research Council, Canada
11:30 AM
Plans and Progress with developing and licensing a Hia vaccine
Luis Barreto, MD, National Research Council, Canada
See more of: Invited Symposia